Stem Cell Clinic

Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual…

By Global News Feed

LEXINGTON, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced results from preclinical studies of KER-012 at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting Virtual Event held September 11-15, 2020.

Excerpt from:
Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual...

Adamas Announces New Employment Inducement Grant

By Global News Feed

EMERYVILLE, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 269,250 shares of the company’s common stock, at a per share exercise price of $5.12, the closing trading price on September 8, and restricted stock units to acquire 2,125 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

Read more:
Adamas Announces New Employment Inducement Grant

AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference

By Global News Feed

SAN DIEGO, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the 2020 Cantor Global Virtual Healthcare Conference on Thursday, September 17, 2020 at 12:00 p.m. ET. The conference will be conducted virtually, and the presentation will be available via https://www.webcaster4.com/Webcast/Page/2495/37348

Read more:
AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference

Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference

By Global News Feed

DUBLIN, Ireland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, today announced that its executive team will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference taking place September 14 – 16, 2020.

Read more here:
Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial

By Global News Feed

NEW YORK and MAINZ, GERMANY, Sept. 12, 2020 (GLOBE NEWSWIRE) --  NEW YORK and MAINZ, GERMANY, September 12 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced today that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations.

See the original post here:
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial

→←